Sandu Pharmaceuticals Limited

Equities

SANDUPHQ6

INE751D01014

Pharmaceuticals

Market Closed - Bombay S.E. 11:00:51 29/05/2024 BST 5-day change 1st Jan Change
58.47 INR -1.32% Intraday chart for Sandu Pharmaceuticals Limited -4.74% -14.14%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sandu Pharmaceuticals Limited Appoints Shri Vijay Kajrekar as Chief Financial Officer CI
Sandu Pharmaceuticals Limited Announces Executive Changes CI
Sandu Pharmaceuticals Board Mulls CFO Appointment MT
Sandu Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sandu Pharmaceuticals CFO to Step Down in December MT
Sandu Pharmaceuticals Limited Announces CFO Changes CI
Sandu Pharmaceuticals' Consolidated Net Profit Slips in Fiscal Q2 MT
Sandu Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sandu Pharmaceuticals Limited Approves Change in Directorate CI
Sandu Pharmaceuticals Shuts Goa, India Plant for Renovation MT
Sandu Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Sandu Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended 31St March 2023 CI
Sandu Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sandu Pharmaceuticals Expands Partnership with Vietnam's Bach Ma Van Xuan; Shares Jump 3% MT
Sandu Pharmaceuticals Limited Enters into Memorandum of Understanding with Bach Ma Van Xuan Pharmaceuticals CI
Sandu Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Sandu Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022 CI
Sandu Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended 31 March 2022 CI
Sandu Pharmaceuticals Forms New Subsidiary for Phytoceuticals Products MT
Sandu Pharmaceuticals Limited Incorporates Subsidiary CI
Sandu Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Sandu Pharmaceuticals Plans New Phytoceutical Product Subsidiary MT
Sandu Pharmaceuticals Limited Announces Formation of A Wholly Owned Subsidiary Company CI
Sandu Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Sandu Pharmaceuticals Limited Approves Appointment of K Vinay Kumar as Chairman CI
Chart Sandu Pharmaceuticals Limited
More charts
Sandu Pharmaceuticals Limited is an India-based company, which is mainly engaged in the business of manufacturing and trading of ayurvedic medicines under the brand name, SANDU. The Company's product category includes digestive health, immunity, muscle and bone health, respiratory health, wellness, and others. Its digestive health products focus on constipation, hyperacidity, indigestion and flatulence, and loose motions, among others. Its wellness products cover female wellness, male wellness and mother and child. Its respiratory health products focus on respiratory health, asthma, and cold and cough. Its ayurveda category includes herbs, panchakarma, dincharya, rutucharya, ahar vihar, arogyadarshika, prakruti and yoga. The Company also offers products, such as an immunity kit and a power herbs range. Its products are manufactured using in-house know-how supplied by Sandu Brothers Private Limited. The Company's products are sold through e-commerce marketplaces.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. SANDUPHQ6 Stock
  4. News Sandu Pharmaceuticals Limited
  5. Sandu Pharmaceuticals Expands Partnership with Vietnam's Bach Ma Van Xuan; Shares Jump 3%